Complete IBIO Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
IBIO DCF Analysis
IBIO (iBio, Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2022 (Historical) | 2023 (Historical) | 2024 (Historical) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $0 | $225.0K | $202.5K | $182.3K | $164.0K | $147.6K | $132.9K |
| Revenue Growth % | - | -100.0% | Infinity% | -10.0% | -10.0% | -10.0% | -10.0% | -10.0% |
| EBIT | $-49.7M | $-29.3M | $-16.6M | $10.1K | $9.1K | $8.2K | $7.4K | $6.6K |
| EBIT Margin % | -2085.2% | 0.0% | -7392.9% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| NOPAT | $-37.3M | $-22.0M | $-12.5M | $7.6K | $6.8K | $6.2K | $5.5K | $5.0K |
| NOPAT Margin % | -1563.9% | -Infinity% | -5544.7% | 3.8% | 3.8% | 3.8% | 3.8% | 3.8% |
| Capex | $11.6M | $5.7M | $210.0K | $6.1K | $5.5K | $4.9K | $4.4K | $4.0K |
| Capex / Revenue % | 488.0% | Infinity% | 93.3% | 3.0% | 3.0% | 3.0% | 3.0% | 3.0% |
| Depreciation | $3.8M | $1.4M | $1.3M | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| D&A / Revenue % | 159.1% | Infinity% | 555.6% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Change in NWC | $-83.3M | $-10.0M | $7.2M | $0 | $0 | $0 | $0 | $0 |
| NWC Change / Revenue % | -3496.3% | -Infinity% | 3180.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Unlevered FCF | $38.2M | $-16.4M | $-18.6M | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| UFCF % Chg. | - | -142.9% | -13.5% | Infinity% | NaN% | NaN% | NaN% | NaN% |
| FCF / Revenue % | 1603.5% | -Infinity% | -8262.4% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% |
| Discount Factor | - | - | - | 0.921 | 0.849 | 0.782 | 0.721 | 0.664 |
| Present Value of FCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
| Sum of PV of UFCF | - | - | - | $InfinityB | $InfinityB | $InfinityB | $InfinityB | $InfinityB |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 7.0% |
| Tax Rate | 25.0% |
| After Tax Cost of Debt | 5.2% |
| Risk Free Rate | 4.46% |
| Market Risk Premium | 4.3% |
| Beta | 1.19 |
| Cost of Equity | 9.6% |
| Total Debt | $4.5M |
| Market Cap | $13.5M |
| Total Capital | $18.0M |
| Debt Weighting | 24.8% |
| Equity Weighting | 75.2% |
| WACC | 8.5% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $InfinityB |
| Terminal Value | $InfinityB |
| PV of Terminal Value | $InfinityB |
| Cumulative PV of UFCF | $InfinityB |
| Net Debt | $-9.8M |
| Equity Value | $InfinityB |
| Shares Outstanding | 3.8M |
| Implied Share Price | $InfinityB |
| Current Share Price | $1 |
| Implied Upside/(Downside) | +Infinity% |
Valuation Summary
$Infinity
Implied Price
$0.82
Current Price
+Infinity%
Upside/Downside
8.5%
WACC
IBIO Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 8 peer companies in Healthcare
P/E Ratio
$-20.60
-2611.7%
Peer Median: 9.7x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.0x
P/S Ratio
$0.34
-58.9%
Peer Median: 14.8x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for IBIO's business model and current situation.
Multiple Comparison
| Multiple | IBIO Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -0.4x | 9.7x | 9.7x | -104.0% | Undervalued |
| EV/EBITDA | Infinityx | 0.0x | 0.0x | Infinity% | Overvalued |
| P/S Ratio | 36.1x | 14.8x | 7.6x | 143.4% | Overvalued |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.01B | 0.0x | 0.0x | 0.4x | |
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 9.7x | -18.0x | 31.6x | |
| $0.01B | 0.0x | 0.0x | 34.5x | |
| $0.01B | 0.0x | 0.0x | 36.1x | |
| $0.01B | 0.0x | 0.0x | 14.8x | |
| $0.01B | 0.0x | 0.0x | 0.0x | |
| $0.01B | 0.0x | 0.0x | 71.1x |